Dementia can be defined as a clinical syndrome characterized by a cluster of symptoms and signs manifested by difficulties in memory, disturbances in language and other cognitive functions, changes in behaviors, and impairments in activities of daily living. Alzheimer’s disease (AD), which is named after the German psychiatrist Alois Alzheimer, who first described this disorder more than one century ago, is the most common cause of dementia, accounting for up to 75% of all dementia cases. Alzheimer’s disease is a progressive neurodegenerative disorder. During the last a few decades, research in epidemiology of dementia and AD has made tremendous progress. In this review, we briefly summarize the major findings from the recent epidemiologic studies of AD concerning occurrence (global prevalence, incidence, and impact), determinants (risk and protective factors), and possible strategies toward intervention.

Global population aging, occurrence, and impact of Alzheimer’s disease

Population aging has become a worldwide universal phenomenon. The reports from the UN Aging Program and the US Centers for Disease Control and Prevention have projected that the number of older people (65+ years) in the world is expected to increase from 420 million in 2000 to nearly 1 billion by 2030, with the proportion of older people being increased from 7% to 12%. Developing countries will see the largest increase in absolute numbers.

Author affiliations: Aging Research Center, Karolinska Institutet-Stockholm University and Stockholm Gerontology Research Center, Stockholm, Sweden

Address for correspondence: Dr Chengxuan Qiu, Aging Research Center, Karolinska Institutet, Gävlegatan 16, S-113 30 Stockholm, Sweden (e-mail: chengxuan.qiu@ki.se)
bers of older persons. Thus, the developing nations’ share of the worldwide aging population will increase from 59% to 71%. Because occurrence of AD is strongly associated with increasing age, it is anticipated that this dementing disorder will pose huge challenges to public health and elderly care systems in all countries across the world.

Prevalence of Alzheimer’s disease

The pooled data of population-based studies in Europe suggests that the age-standardized prevalence in people 65+ years old is 6.4% for dementia and 4.4% for AD. In the US, the study of a national representative sample of people aged >70 years yielded a prevalence for AD of 9.7%. Worldwide, the global prevalence of dementia was estimated to be 3.9% in people aged 60+ years, with the regional prevalence being 1.6% in Africa, 4.0% in China and Western Pacific regions, 4.6% in Latin America, 5.4% in Western Europe, and 6.4% in North America. More than 25 million people in the world are currently affected by dementia, most suffering from AD, with around 5 million new cases occurring every year. The number of people with dementia is anticipated to double every 20 years. Despite different inclusion criteria, several meta-analyses and nationwide surveys have yielded roughly similar age-specific prevalence of AD across regions (Figure 1). The age-specific prevalence of AD almost doubles every 5 years after aged 65. Among developed nations, approximately 1 in 10 older people (65+ years) is affected by some degree of dementia, whereas more than one third of very old people (85+ years) may have dementia-related symptoms and signs. There is a similar pattern of dementia subtypes across the world, with AD and vascular dementia, the two most common forms of dementia, accounting for 50% to 70% and 15% to 25%, respectively, of all dementia cases.

Epidemiologic research of dementia and AD in low- and middle-income countries has drawn much attention in recent years. A systematic review estimated that the overall prevalence of AD in developing countries was 3.4% (95% CI, 1.6%–5.0%). The 10/66 Dementia Research Group found that the prevalence of dementia (DSM-IV criteria) in people aged 65+ years in seven developing nations varied widely from less than 0.5% to more than 6%, which is substantially lower than in developed countries. Indeed, the prevalence rates of dementia in India and rural Latin America were approximately a quarter of the rates in European countries. However, the prevalence of AD in persons 65+ years in urban areas of China was 3.5%, and even higher (4.8%) after post-hoc correction for negative screening errors, which is generally comparable with those from Western nations. Similar prevalence rates of dementia were also reported from the urban populations of Latin American nations such as Havana in Cuba (6.4%) and São Paulo in Brazil (5.1%).

Figure 1. Age-specific prevalence of Alzheimer’s disease (per 100 population) across continents and countries. *, prevalence of all types of dementia

Selected abbreviations and acronyms

| Abbreviation | Description |
|--------------|-------------|
| AD           | Alzheimer’s disease |
| APOE         | apolipoprotein E |
| BMI          | body mass index |
| ELF-EMF      | extremely-low-frequency electromagnetic fields |
| HYVET-COG    | Hypertension in the Very Elderly Trial-Cognitive Function Assessment |
| MCI          | mild cognitive impairment |
| PROGRESS     | Perindopril Protection Against Recurrent Stroke Study |
| SCOPE        | Study on Cognition and Prognosis in the Elderly |
| Syst-Eur     | Systolic Hypertension in Europe Trial |
| WHI-MS       | Women’s Health Initiative-Memory Study |
Incidence of Alzheimer’s disease

The pooled incidence rate of AD among people 65+ years of age in Europe was 19.4 per 1000 person-years. The pooled data from two large-scale community-based studies of people aged 65+ years in the US Seattle and Baltimore areas yielded an incidence rate for AD of 15.0 (male, 13.0; female, 16.9) per 1000 person-years. The incidence rate of AD increases almost exponentially with increasing age until 85 years of age (Figure 2). However, it remains uncertain whether the incidence continues to increase, even at more advanced ages, or reaches a plateau at a certain age; this is relevant for projecting the burden of the disease as well as for understanding its etiology. For instance, a consistently exponential increase with advancing age in Alzheimer incidence suggests that AD is an inevitable consequence of aging, whereas a convergence to or a decline at certain age may suggest that very old people may have reduced vulnerability, owing perhaps to genetic or environmental factors. The Cache County Study further found that the incidence of AD increased with age, peaked, and then started to decline at extreme old ages for both men and women. However, some meta-analyses and large-scale studies in Europe provided no evidence for the potential decline in the incidence of dementia and AD among the oldest-old age groups. The apparent decline suggested in some studies may be an artifact of poor response rate and survival effect in these very old age groups. Several studies from Europe observed a higher incidence rate of AD among women than men, especially among the oldest-old age groups, whereas studies in North America generally found no significant gender difference. There appears to have been some geographic variations in the incidence of AD. The pooled data of eight European studies suggested a geographical dissociation across Europe, with higher incidence rates being found among the oldest-old people of north-western countries than among southern countries. The incidence rates of AD were reported to be slightly lower in North America than in Europe. Differences in methodology (eg, differences in study design and procedure of case ascertainment), rather than real different regional distributions of the disease, may be partly responsible for the geographic variations. The study using identical methods in UK found no evidence of variation in dementia incidence among five areas in England and Wales. Studies have confirmed that AD incidence in developing countries is generally lower than in North America and Europe. For example, the incidence rate of AD among people aged 65+ years was 7.7 per 1000 person-years in Brazil and 3.2 per 1000 person-years in India.

Impact of Alzheimer’s disease at individual and societal levels

At the individual level, AD significantly shortens life expectancy and is one of the principal causes of physical disability, institutionalization, and decreased quality of life among the elderly. First, AD is strongly associated with functional disability and institutionalization. It is estimated that among individuals over 60 years of age dementia contributes 11.2% of the years lived with disability, compared with 9.5% for stroke, 8.9% for musculoskeletal disorders, and 5.0% for cardiovascular disease. The follow-up studies of people aged 75+ years in Sweden have shown that approximately half of the elderly people who develop functional dependence over a 3-year period can be attributable to dementia and AD. In many industrialized countries, dementia is the most common disease among older adults living in nursing homes or in institutions. Second, epidemiologic studies have confirmed the malignant nature of AD that could confers an excess risk of death for older people in a similar extent to that of malignant tumors. Several community-based follow-up studies of

Figure 2. Age-specific incidence of Alzheimer’s disease (per 1000 person-years) across continents and countries. *, incidence of all types of dementia.
incident cases showed that AD was associated with a two- to fivefold increased risk of death.\textsuperscript{28,29} The long-term follow-up study also showed that AD was associated with relative risk of 2.6 for mortality, although the strength of association was diluted after controlling for multimorphologies.\textsuperscript{28} Overall, the median survival time for people with newly diagnosed AD ranges from 3 to 6 years.\textsuperscript{28} Older age, male sex, white race, low education, comorbidities (eg, hypertension, diabetes, and heart disease), poorer cognitive function, and physical disability are frequently reported to predict a shorter survival in persons with AD.\textsuperscript{28,32}

The rapid increase in the number of patients with dementia and AD will result in tremendous consequence for our society and economy. The number of persons with AD in the US population in 2000 was estimated to be 4.5 million, and by 2050 this number was projected to increase by almost threefold, to 13.2 million.\textsuperscript{33} The more recent study indicated that in 2006 the worldwide total number of patients with AD was 26.6 million, and by 2050 the number will quadruple.\textsuperscript{7} It was estimated that about 43\% of AD patients require a high level of care such as nursing home and institutions. The long-term institutional care will be the main cost in many developed countries, whereas in developing countries informal home care provided by family members is usually the only source available for patients with dementia.\textsuperscript{12} Even in the US, almost 10 million Americans (eg, family members, friends, and neighbors) provided unpaid care for persons with AD or other dementia.\textsuperscript{33} Thus, enormous resources will be needed for adequate care of Alzheimer and dementia patients. The worldwide overall societal costs of dementia were estimated to be more than US$315 billion in 2005, including one third for informal care;\textsuperscript{35} approximately three fourths of the global costs for dementia occurred in middle-income countries where about 46\% of dementia patients reside.\textsuperscript{12} The 2009 reports from Alzheimer’s Association showed that in US the annual costs for patients with AD and other dementia were estimated to be US$148 billion plus US$94 billion unpaid care service, and that AD tripled health care costs for Americans aged 65+ years.\textsuperscript{34} It has reported that the costs for dementia are higher than those related to diabetes and smoking.\textsuperscript{35} Thus, AD will place heavy economic burden on the family and society due to the needs of persistent care and therapy. It was anticipated that modest advances in therapeutic and preventive strategies that lead to even a 1-year delay in the onset and progression of clinical AD, would significantly reduce the global burden of this disease.\textsuperscript{7,37}

### Determinants of Alzheimer’s disease

Alzheimer’s dementia is a multifactorial disease, in which older age is the strongest risk factor, suggesting that the aging-related biological processes may be implicated in the pathogenesis of the disease. Furthermore, the strong association of AD with increasing age may partially reflect the cumulative effect of different risk and protective factors over the lifespan, including the effect of complex interactions of genetic susceptibility, psychosocial factors, biological factors, and environmental exposures experienced over the lifespan. Following various etiologic hypotheses, Table I summarizes the major risk and protective factors for AD.\textsuperscript{38} Moderate to strong evidence, most from epidemiologic, neuroimaging, and neu-

| Etiologic hypothesis          | Contents: risk and protective factors                                                                 | Epidemiologic evidence                  |
|------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------|
| Genetic susceptibility        | Risk factors: APOE ε4 allele and familial aggregation                                                  | Strong                                 |
| Vascular pathway hypothesis   | Risk factors: midlife high blood pressure and high BMI, diabetes, cerebrovascular disease, and smoking; Protective factors: light-to-moderate alcohol consumption, and antihypertensive therapy | Moderate or sufficient                  |
| Psychosocial hypothesis       | Protective factors: high educational attainment, mentally stimulating activities, social activity and enriched social network, and physical activity | Moderate or sufficient                  |
| Nutritional and dietary      | Risk factors: deficiency in folate, vitamin B12, and antioxidants (vitamins A, E, and C); Protective factors: Fish (omega-3 fatty acids) and vegetable consumption. | Insufficient or limited/mixed          |
| hypothesis                    |                                                                                                       |                                        |
| Others (eg, toxic or inflammatory factors) | Risk factors: traumatic head injuries, occupational exposure to toxins and electromagnetic fields, depression, and hormone replacement therapy; Protective factors: nonsteroidal anti-inflammatory drugs | Insufficient or limited/mixed          |

Table I. Summary of risk and protective factors for Alzheimer’s disease by various etiologic hypotheses.
ropathological research, supports the role of genetic, vascular, and psychosocial factors in the development of AD, whereas evidence for the etiologic role of other factors (eg, dietary or nutritional factors, occupational exposures, and inflammation) is mixed or insufficient.

**Genetic hypothesis**

Early-onset familial AD is often caused by autosomal dominant mutations (eg, mutations in amyloid precursor protein, presenilin-1, and presenilin-2 genes), which accounts for only about 2% to 5% of all Alzheimer patients. The majority of AD cases are sporadic and present considerable heterogeneity in terms of risk factor profiles and neuropathological features. First-degree relatives of Alzheimer patients have a higher lifetime risk of developing AD than the general population or relatives of nondemented individuals; both genetic and shared environmental factors contribute to the phenomenon of familial aggregation. In addition, some studies suggest that the familial aggregation of AD can only be partially explained by known genetic components such as the apolipoprotein E (APOE) ε4 allele, indicating that other susceptibility genes may be involved. The APOE ε4 allele is the only established genetic factor for both early- and late-onset AD; it is a susceptibility gene for AD, being neither necessary nor sufficient for AD development. With increasing number of the APOE ε4 alleles, the risk of AD increases and the age of AD onset decreases, in a dose-dependent manner. The risk effect of APOE ε4 allele on AD decreases with increasing age, and overall approximately 15% to 20% of Alzheimer cases are attributable to the ε4 allele. Several other candidate genes, many of them vascular related such as angiotensin-I converting enzyme, cholesterol 24-hydroxylase, and insulin-degrading enzyme genes, have been studied, but with inconsistent findings.

**Vascular pathway hypothesis**

Moderate to strong evidence from multidisciplinary research (epidemiologic, neuroimaging, and neuropathological studies) has emerged supporting the hypothesis that vascular risk factors (eg, smoking, obesity, and high total cholesterol) and vascular morbidity (eg, high blood pressure, diabetes, and silent brain infarcts and white matter lesions) are associated with an increased risk of dementia, including AD.

**Tobacco use**

Earlier cross-sectional studies often reported lower prevalence rates of AD among smokers than nonsmokers. However, this protective effect was probably due to selective survival bias related to smoking because smokers are proportionally less numerous among prevalent cases; when incident AD cases were examined, such an effect was no longer present. Contrary to the cross-sectional studies, many follow-up studies found a significantly increased risk of AD associated with cigarette smoking, especially among noncarriers of the APOE ε4 allele. Meta-analyses of follow-up studies concluded that current smoking was associated with an increased risk of AD (pooled relative risk, 1.79; 95% CI, 1.43–2.23). Thus, in contrast to the initial hypothesis of a possible protective effect, cigarette smoking actually increases the risk of AD.

**Alcohol consumption**

It is known that alcohol abuse can cause “alcoholic dementia.” The deleterious effect of heavy alcohol intake emerges from a study suggesting that heavier drinkers at middle age had a more than threefold increased risk of dementia and AD in late life, especially among carriers of the APOE ε4 allele. By contrast, light-to-moderate alcohol consumption was frequently reported to be associated with a reduced incidence of dementia and AD, leading to the hypothesis that light-to-moderate alcohol intake may protect against the development of dementia. However, the role of moderate alcohol consumption in dementia remains controversial because the inverse association may be due to information bias, the confounding of healthy lifestyles and high socioeconomic status, different approaches in assessments of alcohol consumption, or outcome misclassification. Indeed, alcohol may have beneficial influences on several cardiovascular factors, including lipid and lipoprotein levels, and inflammatory, and hemostatic factors. Moderate alcohol drinking has been related to a reduced risk of cardiovascular diseases, and may be associated with fewer brain infarcts. Furthermore, a U-shaped relationship of alcohol consumption with the burden of white matter lesions has been described. On the other hand, excessive alcohol drinking has clear detrimental effects on the brain, and even light-to-moderate alcohol drinking has been related to increased brain atrophy and to smaller brain volumes.
State of the art

Overweight and obesity

The lifespan-dependent relationship between body mass index (BMI) and risk of dementia has emerged in a systematic review such that a higher BMI in midlife is a risk factor for AD and dementia, whereas an accelerated decline in BMI during late life may anticipate the occurrence of the dementing disorders. A higher BMI or obesity (especially central obesity) at the age of around 50 years was related to an increased risk of dementia occurring 20 to 25 years later. The long-term follow-up study of Japanese-American men revealed a greater decline in BMI approximately 10 years prior to dementia onset. The Cardiovascular Health Study also provided insight into the age-dependent BMI-dementia relationship, in which obesity at midlife (around 50 years of age) was related to a higher risk of late-life development of dementia, whereas BMI measured after age 65 years was inversely related to dementia risk. In line with these findings, several follow-up studies of older people suggested that accelerated decline in BMI was associated with future development of AD. Low BMI in late life was related to a higher risk for AD over a subsequent 5- to 6-year period. Thus, late-life low BMI and weight loss can be interpreted as markers for preclinical AD, particularly when measured just a few years prior to clinical diagnosis of the disease.

Blood pressure and blood pressure-lowering therapy

Elevated blood pressure in middle age, especially uncontrolled midlife high blood pressure, was linked to an increased risk of late-life AD in several observational studies. Findings from follow-up studies of late-life blood pressure in relation to the risk of dementia have been inconsistent; several follow-up studies, especially those with a relatively short period of follow-up (eg, <3 years), found no association or even an inverse association between level of blood pressure and risk of dementia and AD. As dementia has a long latent period and blood pressure may be lowered at its preclinical phase, the lack or an inverse association can be interpreted as a consequence of the disease process. However, studies with a longer follow-up period follow-up (eg, >6 years) have also reported an inverse association suggesting that low blood pressure in late life may contribute to the development or clinical expression of dementia and AD.

Longitudinal studies repeatedly show a protective effect of use of antihypertensive drugs against dementia and AD. Recent follow-up studies have suggested that the protective effect of antihypertensive therapy on dementia and AD may depend on the duration of treatment and the age when people take the medications; the more evident efficacy was seen among younger-old people (eg, <75 years) and those with long-term treatment. Evidence from clinical trials of antihypertensive therapy and dementia is summarized in the section on intervention trials towards primary prevention. Antihypertensive treatment may protect against dementia and AD by postponing atherosclerotic process, reducing the number of cerebrovascular lesions, and improving cerebral perfusion. It has also been suggested that some antihypertensive agents (eg, calcium-channel antagonists) may have neuroprotective effects. The recent neuropathological study found substantially less Alzheimer neuropathological changes (ie, neuritic plaque and neurofibrillary tangle densities) in the medicated hypertension group than nonhypertensive group, which may reflect a salutary effect of antihypertensive therapy against AD-associated neuropathology.

High serum cholesterol and use of cholesterol-lowering drugs (statins)

High serum total cholesterol at midlife was linked to an increased risk of late-life AD. The late-life high cholesterol in relation to dementia and AD is less clear, with studies indicating either no association or an inverse association of hypercholesterolemia with subsequent development of AD. A bidirectional influential relationship between serum total cholesterol and dementia has been suggested; high total cholesterol at middle age is a risk factor for the development of AD and dementia 20 years later, but decreasing serum cholesterol after midlife may reflect ongoing disease processes and may represent a marker for late-life AD and dementia. A pattern of decrease in blood pressure and BMI from midlife to older adults has also been described, but decline in total cholesterol shows somewhat different patterns. The dementia-associated additional decline in blood pressure and BMI generally becomes detectable about 3 to 6 years before the clinical expression of the disease, while the decline in total cholesterol seems to start much earlier, and with less evident acceleration prior to dementia onset. These changes may explain, at least partly, the inconsistent results from
the cross-sectional and short-term follow-up studies as well as studies having the measurement of serum cholesterol later in life.

Little information is currently available regarding the roles of subtype cholesterols (low-density lipoprotein, high-density lipoprotein, and triglycerides) in AD. It is important to note that serum and brain cholesterol are two separate pools, and links between them are not totally understood. One possible pathway is represented by oysterol, mono-oxygenated metabolites of cholesterol, with the unique ability to cross the blood-brain barrier.95 The currently available epidemiological and clinical data on use of lipids lowering drugs (statins) and risk of AD give a rather mixed picture. Several cross-sectional and case-control studies have reported that statin users have a considerable lower prevalence of AD.94,95 While the follow-up data from the Rotterdam Study showed that use of statins was associated with a lower risk of AD independent of lipophilicity of statins,96 other prospective studies have indicated that there is no beneficial effect or only modestly decreased risk of AD related to statin use.97,98 Neuropathological studies also showed inconsistent findings as to whether the use of statins was associated with the burden of Alzheimer pathological changes and infarcts in the brain.96,100 Experimental studies suggest that statins may reduce β-amyloid production in vitro and in vivo. Statins also have a variety of actions that may benefit the central nervous system and reduce the risk of AD, including endothelial protection via actions on the nitric oxide synthase system, antioxidant, anti-inflammatory, and antiplatelet effects.

Nutritional and dietary factors

Several follow-up studies have reported a decreased risk of AD associated with increasing dietary or supplementary intake of antioxidants (eg, vitamins E and C).100,101 although some negative findings were also reported.102 Furthermore, studies found that higher adherence to “Mediterranean diet” (ie, a dietary pattern with higher intake of fish, fruits, and vegetables rich in antioxidants) was associated with a reduced risk of AD independent of vascular pathways.104,105 In addition, mixed results have been reported on the association of serum vitamin B12, folate, and homocysteine with the risk of dementia and AD.106 The Cochrane systematic review concluded that folic acid and vitamin B12 supplements have no benefits on cognition, although folate plus vitamin B12 are effective in reducing serum homocysteine.107 Finally, it has been reported that a diet rich in saturated fats and cholesterol increases the risk of AD,108 whereas polyunsaturated fatty acids and fish may be protective against dementia.109,110

Unsaturated fatty acids may confer protection through anti-inflammatory properties. Fatty acids may also play a part in the synthesis and fluidity of nerve cell membranes and for synaptic plasticity and neuronal degeneration. In addition, oxidative stress is one of the central features in the Alzheimer brain. Thus, it may be plausible that supplementation or diet rich in antioxidants such as fruits, vegetables, and vitamins E and C might protect against AD.

Diabetes

An increased risk of not only vascular dementia but also neurodegenerative type dementia among persons with diabetes has been reported in several longitudinal studies,111-113 and the risk effect was confirmed by a systematic review.114 Midlife diabetes or a longer duration of diabetes may play a crucial role in dementia and AD.115,116 In addition, borderline or prediabetes or impaired glucose tolerance is also linked to an increased risk of dementia and AD in very old people.117 Such an association may reflect a long-term direct effect of uncontrolled hyperglycemia on neurodegenerative changes in the brain or an effect of hyperinsulinemia or impaired insulin response, or due to diabetes-related comorbidities such as hypertension and dyslipidemia.118-120 The metabolic syndrome, which is a cluster of multiple vascular risk factors characterized by abnormalities in insulin, blood glucose, lipoprotein metabolism, hypertension, and obesity, was found to be associated with an increased prevalence of AD in an elderly Finnish population.121 However, the follow-up study of multiethnic elderly cohort in the US found no association of the metabolic syndrome with either prevalent or incident AD, but two components of the syndrome, diabetes and hyperinsulinemia, were associated with an increased risk of incident AD122; the authors concluded that examining diabetes and hyperinsulinemia separately might be preferable to using the metabolic syndrome as a single factor to define the risk of AD.

Cerebral and cardiovascular disease

Stroke, and even clinically silent brain infarcts and white-matter hyperintensities seen on magnetic
resonance imaging (MRI) scans, significantly increased the risk of dementia and AD, although the observed association with AD has been argued to actually reflect an association with mixed dementia. The follow-up data of the Cardiovascular Health Study showed that cardiovascular disease was associated with an increased incidence of dementia and AD, with the highest risk of dementia being seen in people with peripheral arterial disease, suggesting that extensive peripheral atherosclerosis is a risk factor for AD. Other cardiovascular disease (eg, atrial fibrillation and heart failure) and more severe atherosclerosis measured with ankle-to-brachial index have been related to dementia and AD as well. Neuropathological studies suggested that cerebrovascular lesions, atherosclerosis, and neurodegenerative changes in the brain often coexist, and may be coincident processes converging to cause additive damage to the aging brain and to promote clinical expression of the dementia syndrome.

Psychosocial hypothesis

A systematic review found that psychosocial factors and actively integrated lifestyle over the lifespan may reduce the risk of AD and dementia. These factors include early-life high educational attainment, adult-life high work complexity, late-life rich social network and high levels of social engagement, and more frequently participating in physically and mentally stimulating activity.

High educational attainments and socioeconomic status

An association of low education with an increased risk of dementia and AD has been reported in numerous cross-sectional and longitudinal studies. Education and socioeconomic status are highly correlated; when both measures were examined simultaneously, the independent association was detected only with education. The reserve hypothesis has been proposed to interpret this association such that education could enhance neural and cognitive reserve that may provide compensatory mechanisms to cope with degenerative pathological changes in the brain, and therefore delay onset of the dementia syndrome. Alternatively, educational achievement may be a surrogate or an indicator of intelligent quotient, early life living environments, and occupational toxic exposure experienced over adulthood.

Social network and social engagement

Evidence from longitudinal observational studies suggests that a poor social network or social disengagement is associated with cognitive decline and dementia. The risk for dementia and AD was also increased in older people with increasing social isolation and less frequent and unsatisfactory contacts with relatives and friends. Furthermore, a recent study suggested that low neuroticism in combination with high extraversion was the personality trait associated with the lowest dementia risk, and among socially isolated individuals even low neuroticism alone seemed to decrease the risk of dementia. Finally, low social engagement in late life and a decline in social engagement from middle age to late life were associated with a doubly increased risk of developing dementia and AD in late life. Rich social networks and high social engagement imply better social support, leading to better access to resources and material goods. Rich and large social networks also provide affective and intellectual stimulation that could influence cognitive function and different health outcomes through behavioral, psychological, and physiological pathways.

Physical activity

Regular physical exercise was reported to be associated with a delay in onset of dementia and AD among cognitively healthy elderly. In the Kungsholmen Project, the component of physical activity presenting in various leisure activities, rather than sports and any specific physical exercise, was related to a decreased dementia risk. In addition, low-intensity activity such as walking may reduce the risk of dementia and cognitive decline. A strong protective effect of regular physical activity in middle age against the development of dementia and AD in late life was reported, especially for persons with the APOE ε4 allele. As it may take years to achieve high levels of physical fitness, brief periods of exercise training may not have substantial benefits on cognitive processes, but could still be detectable in the subsets of cognitive domains that are more sensitive to the age-related decrements. Physical activity is important not only in promoting general and vascular health, but also in promoting brain plasticity, and it may also affect several gene transcripts and neurotrophic factors that are relevant for the maintenance of cognitive functions.
**Mental activity**

Various types of mentally demanding activities have been examined in relation to dementia and AD, including knitting, gardening, dancing, playing board games and musical instruments, reading, social and cultural activities, and watching specific television programs, which often showed a protective effect. Due to the cultural and individual differences in choosing specific activities, some researchers summarize mentally stimulating activities into a composite score, which showed that a cognitive activity score involving participation in seven common activities with information processing as a central component was associated with a reduced risk of AD, even after controlling for APOE ε4 allele, medical conditions, and depressive symptoms. The Swedish Twin Study showed that greater complexity of work, and particularly complex work with people, may reduce the risk of AD. The Canadian Study of Health and Aging found that high complexity of work appeared to be associated with a reduced risk of dementia, but mostly for vascular dementia. In supporting of these findings, the recent neuroimaging study suggested that a high level of complex mental activity across the lifespan was correlated with a reduced rate of hippocampal atrophy.

**Other etiologic hypotheses (inflammation, toxic exposure, and other factors)**

**Inflammation**

A higher level of serum C-reactive protein (CRP) in midlife was linked to an increased risk of both Alzheimer type and vascular dementias, suggesting that inflammatory markers may reflect both peripheral disease and cerebral mechanisms related to dementia, and that these processes are measurable for a long time before dementia is manifested. Follow-up studies of older adults also showed an association of serum inflammatory markers (eg, CRP and interleukin-6) measured at older ages with an increased incidence of dementia and AD. As additional evidence supporting the inflammatory involvement in AD and dementia, recent follow-up studies and the systematic review of observational studies concludes that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ≥2 years) may have beneficial effect against AD and dementia. In addition, experimental research found that neuritic plaques in the brain are associated with inflammatory proteins. Therefore, it seems plausible to hypothesize that inflammatory mechanisms may play a role in the processes leading to neurodegeneration. However, neuropathological studies found no evidence for an association between use of NSAIDs and reduced burden of AD pathological changes. Furthermore, the results from the clinical trial of anti-inflammatory drugs (celecoxib or naproxen) in AD prevention, which was suspended due to increased cardiovascular risks associated with celecoxib, failed to show any beneficial effect of using these drugs against AD, instead, an increased risk for AD related to drug therapy were observed (see section on Intervention trials toward primary prevention).

**Toxic exposures**

Manual work as the lifetime principal occupation has been related to AD and dementia in some studies, suggesting a possible implication of occupational toxic exposures in the development of the dementia disorders. Occupational exposures to heavy metals such as aluminum and mercury have been suggested as a risk factor for AD, and even high consumption of aluminum from drinking water may be a risk factor for AD. However, this has not been confirmed. In addition, occupational exposure to extremely-low-frequency electromagnetic fields (ELF-EMF) has been related to an increased risk of dementia and AD in a number of follow-up studies. The meta-analysis of epidemiological evidence suggests an association between occupational exposure to ELF-EMF and AD. The biological plausibility linking ELF-EMF to AD has been previously described.

**Other factors**

First, traumatic brain injury has been extensively investigated as a possible risk factor for AD. The meta-analysis of case-control studies supported an association between a history of previous head injury and the risk of developing AD. In contrast, some longitudinal studies found that AD risk was not associated with head trauma or associated with only severe head injury. Second, an association between hormone replacement therapy and a reduced risk of dementia and AD among postmenopausal women had been frequently reported in numerous observational studies until 2004 when, instead of a protective effect, a significantly increased risk of dementia associated with estrogen therapy was found in the Women’s Health...
Study (see section on intervention trials toward primary prevention). Finally, several studies have reported an association between depression and an elevated risk of later development of dementia and AD, but it remains arguable as to whether depression is a preclinical symptom or a pure risk factor for dementia and AD.\textsuperscript{172-174}

Interventions toward Alzheimer's disease

Current evidence tends to support the notion that dementia onset may be postponed by implementing interventions toward the potential etiologic factors (both risk and protective factors) (ie, primary prevention) and by early detection (ie, secondary prevention), whereas appropriate care and pharmacotherapy for patients with AD and dementia (ie, tertiary prevention) may help stabilize cognitive functions, reduce agitation, control neuropsychiatric symptoms, and improve the quality of life.

Interventions toward primary prevention

Primary intervention strategies

Theoretically, even if the mechanisms of vascular and psychosocial factors being involved in the pathogenesis and clinical expression of AD are still not fully understood, primary prevention seems possible as most vascular factors and disorders, psychosocial factors, and lifestyle factors are modifiable or amenable to management.\textsuperscript{38,175} One intervention strategy is to target vascular pathways, including management of midlife high blood pressure and obesity, high blood glucose level, and diabetes. In addition, preventing recurrent cerebrovascular disease and maintaining sufficient cerebral blood perfusion by adequately managing heart failure and avoiding very low blood pressure may help postpone clinical expression of the dementia syndrome, especially among very old people. The second strategy is to maintain the more active and socially integrated lifestyles by establishing extensive social networks and frequently participating in social, physical, and intellectually stimulating activities, which may reduce the risk or delay the onset of AD.\textsuperscript{38,132} Taken together, the most effective strategy may be to encourage people implementing multiple preventive measures throughout the life course, including high educational attainment in childhood and early adulthood, active control of vascular factors and disorders over adulthood, and maintenance of mentally, physically, and socially active lifestyles during middle age and later in life.

Intervention trials toward primary prevention

The main clinical and intervention trials toward primary prevention by targeting the possible risk and protective factors for AD and dementia are summarized in Table II.\textsuperscript{160,161,176-182} Antihypertensive treatments in reducing the risk of dementia and AD have been tested in a few clinical trials. The pooling analysis of the 2007 Cochrane review, based essentially on three clinical trials (SHEP,\textsuperscript{183} Syst-Eur,\textsuperscript{184} and SCOPE\textsuperscript{185}), found no convincing evidence that blood pressure-lowering therapy among elderly individuals with hypertension could prevent dementia. However, in this review the SCOPE trial, which did not show any effect of blood pressure-lowering treatment by candesartan on the risk of dementia, was actually not a placebo-controlled trial due to ethical considerations. By contrast, the placebo-controlled PROGRESS trial among individuals with cerebrovascular disease (transient ischemic attacks and stroke), which did find a beneficial effect of antihypertensive therapy on cognitive function related to recurrent stroke, was not included.\textsuperscript{186} The cognition substudy of the double-blind placebo-controlled Hypertension in the Very Elderly Trial (HYVET-COG) among people 80+ years found a nonsignificant reduction in the risk of dementia related to antihypertensive treatment. Encouragingly, when data from this clinical trial were pooled together with those from three other double-blind placebo-controlled trials (SHEP, Syst-Eur, and PROGRESS), antihypertensive treatment could reduce the risk of dementia by 13\% (hazard ratio, 0.87; 95\% CI, 0.76–1.00; \textit{P}=0.045).\textsuperscript{177} It is worthwhile to notice that dementia or AD was the secondary end point in all major clinical trials of antihypertensive therapy, with a relatively short period of follow-up because the trials had to be terminated when benefits of the treatments were clearly shown in terms of primary end points (usually cardiac and cerebrovascular disease). In this context, if the beneficial effect of lowering blood pressure on dementia is not as strong as for cardiovascular disease, a longer period of observation is needed to demonstrate any significant beneficial effect.

Estrogen therapy among postmenopausal women has been linked to a considerably lower risk of AD and dementia in numerous observational studies, but the large-scale clinical trial of the Women’s Health Initiative Memory Study (WHI-MS) showed that estrogen therapy alone or in combination with progestin did not reduce
incidence of probable dementia and mild cognitive impairment (MCI); instead, the active treatments with estrogen and estrogen plus progestin were found to be associated with a twofold increased risk for both dementia and MCI.\textsuperscript{176,179} It has been argued that in the WHI-MS hormone replacement therapy was given 10 to 15 years after the menopause when the “window of critical time” for putative beneficial effects of estrogen therapy may have been missed.\textsuperscript{187} Other major clinical trials of primary prevention against dementia, such as those with NSAIDs and vitamin E supplementation, have so far failed to confirm any efficacy against dementia and AD (Table II), while more clinical trials (eg, use of cholesterol-lowering drugs and blood glucose lowering drugs) are ongoing.\textsuperscript{188,189} The lack of success in most primary prevention trials underscores the need of new strategies in future intervention studies.

### New strategies for primary prevention: a life-course approach and multidomain interventions

The life-course approach considers biological, environmental, and psychosocial factors acting during early childhood, middle age, and late life as relevant for the development of dementia and AD. This approach seeks to identify the “time windows” when exposures exert the greatest effect on the development of disease and to determine whether concurrent exposures could have interactive effects over the lifespan.\textsuperscript{190} In this context, the risk of late-life dementia and AD is likely to be determined by accumulative effects or complex interactions of genetic, biological, psychosocial, and environmental exposures experienced over the life course. For instance, the brain structural and functional reserve related to education and other psychosocial factors can be conceived as the sum of their lifetime input of education and related activities.\textsuperscript{191} In addition, the life-course

---

**Table II.** Major clinical trials of primary prevention against dementia and Alzheimer’s disease. AD, Alzheimer’s disease; ADAPT, Alzheimer’s Disease Anti-inflammatory Prevention Trial; CI, confidence interval; HR, hazard ratio; HYVET-COG, Hypertension in the Very Elderly Trial-Cognitive Function Assessment; MCI, mild cognitive impairment; SCOPE, Study on Cognition and Prognosis in the Elderly; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe.

| Authors, years | Participants | Interventions | Outcomes | Main findings |
|----------------|-------------|---------------|----------|--------------|
| McGuinness et al,\textsuperscript{176} 2008 | n=15295, age ≥60 years, from SHEP, Syst-Eur, and SCOPE Trials | Blood pressure-lowering therapy | Dementia, AD | Dementia: HR 0.89 (95% CI 0.69–1.16); AD: HR 0.85 (95% CI 0.63–1.15) |
| Peters et al,\textsuperscript{177} 2008 | HYVET-COG: n=3336, age ≥80 years | Blood pressure-lowering therapy | Dementia | HYVET-COG: HR 0.86 (95% CI 0.67–1.09); Meta-analysis: HR 0.87 (95% CI 0.76–1.00), P=0.045 |
| Shumaker et al,\textsuperscript{178} 2004; Espeland et al,\textsuperscript{179} 2004 | n=7479, age ≥65 years, community-dwelling women | Estrogen alone or estrogen plus progestin | Dementia and MCI, cognitive function | Estrogen: dementia: HR 1.76 (95% CI 1.19–2.60); dementia or MCI: 1.38 (1.01–1.89); Estrogen plus progestin: no effect on cognition |
| Heart Protection Study Collaborative Group,\textsuperscript{180,181} 2002 | n=20536, age 40–80 years, had vascular disease, and total cholesterol level ≥3.5 mmol/L | 1. Simvastatin 2. Vitamins E, C, and β-carotene | Dementia and cognitive impairment | Incidence rates: Treatment vs placebo groups: For dementia: 0.3% vs 0.3%; For cognitive impairment: 23.7% vs 24.2% |
| ADAPT Research Group,\textsuperscript{182} 2007; 2008 | n=2528, age ≥70 years, had a family history of AD | Celecoxib or naproxen | AD, cognitive function | AD: celecoxib: HR 2.0 (95% CI 0.8–5.0, P=0.14); naproxen: HR 2.4 (95% CI 0.95–5.8, P=0.06); Cognition: cognitive function was not improved |
| DeKosky et al,\textsuperscript{183} 2008 | n=3069, age ≥75 years, with normal cognition or MCI | Extract of Ginkgo biloba | Dementia, AD | Dementia: HR 1.12 (95% CI 0.94–1.33); AD: HR 1.16 (95% CI 0.97–1.39) |
approach model introduces the concept of “time windows” at exposure, which might be highly relevant for chronic disorders with a long time latent period such as AD. A certain factor might increase the risk of the disease if a subject is exposed during a specific time period, whereas the same factor may show a different effect on the disease in another life period, due to, for example, differential interactions with other factors or selective survival. For instance, high blood pressure and high BMI in midlife are risk factors for late-life dementia, whereas low blood pressure and low BMI among older people are associated with an increased risk of dementia and AD.

Furthermore, intervention studies integrating several different domains of intervention have not yet been implemented so far. The disappointing results of previous intervention trials focusing on a single intervention agent or component in older adults or in already cognitively impaired individuals point out that a few key issues need to be taken into account in future trials: (i) time window of interventions—interventions starting earlier in life may be more effective; (ii) target group—a healthy, relative young population will require relatively long follow-up periods, large sample sizes, and considerable financial resources; and (iii) outcome measures—cognitive impairment may be better than “conversion” to clinical dementia. Several multidomain intervention trials are being planned or ongoing such as the Dose-Response to Exercise Training (DR’s EXTRA), the Cognitive Substudy of the Finnish Diabetes Prevention Study, and the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). In the FINGER study, individuals at an increased risk for developing dementia according to the CAIDE Dementia Risk study, individuals at an increased risk for developing demen-

Secondary prevention

Alzheimer’s disease is characterized by a preclinical phase, possibly lasting years, during which progressive neurodegeneration in the brain is occurring before typical clinical symptoms (eg, cognitive deficits and subtle cognitive disturbances) become detectable. Theoretically, detection of AD at early stage may provide an opportunity for implementing therapeutic intervention to more effectively delay its progression to clinical dementia. However, there remains a challenge as to how to identify individuals during the preclinical phase of the disease, although some clinical markers, neuroimaging biomarkers, and biochemical markers have been investigated. First, numerous studies have suggested that deficits in specific cognitive domains such as episodic memory and verbal ability are conceivable up to 10 years before the dementia syndrome can be clinically diagnosed, with a more evident decline occurring over the final few years. The term “mild cognitive impairment” has been used in clinical settings to identify individuals with isolated memory loss (ie, “amnestic” type MCI), which is more likely to represent the preclinical phase of Alzheimer dementia. However, population-based follow-up studies have frequently shown that individuals with MCI represent a very heterogeneous group in terms of prognosis, although elderly persons with MCI had increased risk of progressing to dementia, a substantial proportion remained stable or even reverted to normal during the next few years. Second, biochemical markers in serum and cerebrospinal fluid such as β-amyloid and τ-protein have been proposed for early detection of AD, although they are not sufficiently reliable in making diagnosis of AD in the presymptomatic phase. Finally, during the last decade neuroimaging has emerged as a useful tool to define AD at both preclinical and early clinical phases of the disease. For example, the amyloid positron emission tomography imaging tracer ligands offer opportunity for measuring β-amyloid in the brain in vivo, which provides the possibility for early diagnosis and for monitoring the course of antiamyloid therapy in AD. Furthermore, the medial-temporal lobe atrophy seen on volumetric MRI has been used in the identification of MCI and early AD as well as in the assessment of progression of MCI and early AD. Successful secondary prevention relies on both reliable detection of the disease at an early stage and availability of efficacious interventions for slowing down progression of the disease. However, while efforts are being made to find ways to effectively counteract the course of AD, some methodo-

State of the art
Tertiary prevention

The tertiary prevention aims to avoid functional disability, and if possible, to improve quality of life for patients with AD. Cognitive training may help maintain cognitive function, slow down cognitive decline, and improve well-being for people with mild dementia. Current medications widely used for AD and dementia, including cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the N-methyl-D-aspartate-receptor antagonist (memantine), are designed to target clinical symptoms of the disease such as cognitive and neuropsychiatric disturbances. The efficacy of antioxidant treatments in AD has not been proven. For example, the Cochrane review found no evidence of efficacy of vitamin E in the treatment of AD and in the prevention of progression of MCI to AD, although the randomized clinical trials of the Physicians’ Health Study II suggested that a long-term β-carotene supplementation might provide cognitive benefits among men. Furthermore, high-dose B vitamin supplements did not slow down cognitive decline among individuals with mild to moderate AD. Intensive research is ongoing in an attempt to develop disease-modifying drugs by targeting the key neuropathological processes in AD such as β-amyloid protein.

Summary

Alzheimer’s disease represents an increasing challenge to public health and the health care system, and has had tremendous impact at both the individual and the societal levels. Epidemiologic research has provided sufficient evidence that vascular risk factors in middle-aged and older adults play a significant role in the development and progression of dementia and AD, whereas extensive social network and active engagement in mental, social, and physical activities may postpone the onset of the dementing disorder. Multidomain intervention trials are warranted to determine to what extent preventive strategies toward optimal control of multiple vascular factors and disorders, as well as the maintenance of an active lifestyle, are effective against dementia and AD.

REFERENCES

1. United Nations Organization. World population ageing: 1950-2050. New York: U. N. P. o. Ageing, United Nations; 2001. www.un.org/esa/population/publications/worldageing19502050/. Accessed March 22, 2009.
2. The Centers for Disease Control and Prevention. Public health and aging: trends in aging – United States and worldwide. JAMA. 2003;289:1371-1373.
3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology. 2000;54:54-59.
4. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-132.
5. Ferri CP, Prince M. Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
6. Wimo A, Winblad B, Agüero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc. Disord. 2003;17:63-67.
7. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3:186-191.
8. Dong MJ, Peng B, Lin XT, Zhao J, Zhou YR, Wang RH. The prevalence of dementia in the People’s Republic of China: a systematic analysis of 1980-2004 studies. Age Ageing. 2007;36:619-624.
9. Sczuzfa M, Menezes PR, Vallada HP, et al. High prevalence of dementia among older adults from poor socioeconomic backgrounds in São Paulo, Brazil. Int Psychogeriatr. 2008;20:394-405.
10. von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999;56:587-592.
11. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 2008;71:337-343.
12. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812-826.
13. Llibre Rodriguez JJ, Ferri CP, Acosta D, et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet. 2008;372:464-474.
14. Zhang ZX, Zähner GE, Roman GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol. 2005;62:447-453.
15. Llibre Rodríguez J, Valhuerdi A, Sanchez I, et al. The prevalence, correlates and impact of dementia in Cuba: a 10/66 group population-based survey. Neuroepidemiology. 2008;31:243-251.
16. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:510-515.
17. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072-2077.
18. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737-1746.
19. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728-733.
20. The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology. 2000;55:66-73.
21. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women:
Epidemiología de la Enfermedad de Alzheimer: frecuencia, determinantes y estrategias orientadas a la intervención

Hoy en día más de 25 millones de personas en el mundo están afectadas por demencia, la mayor parte con Enfermedad de Alzheimer. Tanto en los países desarrollados como en aquellos en vías de desarrollo, la Enfermedad de Alzheimer ha tenido un tremendo impacto en los individuos que la padecen, en los cuidadores y en la sociedad. Los factores etiológicos, más allá de la edad avanzada y la susceptibilidad genética, tienen que ser determinados. Sin embargo, hay una creciente evidencia que apunta fuertemente al papel potencialmente dañino de los factores de riesgo vascular y otros trastornos (fumar cigarrillos, presión alta y obesidad en la edad media de la vida, diabetes y lesiones cerebrovasculares) y al posible papel benéfico de los factores psicosociales (mayor escolaridad, participación social activa, ejercicio físico y actividades de estimulación mental) en el proceso patogénico y en las manifestaciones clínicas de las demencias.

Se espera que las intervenciones a largo plazo, desde múltiples áreas, orientadas al control óptimo de los múltiples factores de riesgo vascular y el mantenimiento de estilos de vida con buena integración social y actividades de estimulación mental reduzcan el riesgo o retarden la instalación de las demencias, incluyendo la Enfermedad de Alzheimer.

Épidemiologie de la maladie d’Alzheimer: survenue, déterminants et stratégies d’intervention

Plus de 25 millions de personnes dans le monde sont aujourd’hui touchées par la démence, la plupart par la maladie d’Alzheimer. Cette maladie affecte de façon très importante les patients atteints, leurs soignants et la société qu’il s’agisse des pays développés ou en voie de développement. Les facteurs étiologiques autres qu’un âge avancé et une susceptibilité génétique restent à déterminer. Le rôle potentiel des facteurs de risque et des maladies vasculaires (tabagisme, hypertension artérielle et obésité de la quarantaine, diabète, lésions cérébrovasculaires) et l’éventuel rôle bénéfique des facteurs psychosociaux (niveau élevé d’éducation, engagement social actif, exercice physique, activité mentalement stimulante) sont cependant de plus en plus fortement mis en évidence dans le processus de la pathogénèse et les manifestations cliniques des troubles démentiels. Les interventions dans plusieurs domaines à long terme pour un contrôle optimal des multiples facteurs de risque vasculaire et le maintien d’un style de vie intégré socialement et d’activités mentalement stimulantes font espérer une réduction du risque ou un report du début clinique de la démence, y compris de la maladie d’Alzheimer.
Epidemiology of Alzheimer's disease - Qiu et al

36. Jónsson B. The economic impact of diabetes. Diabetes Care. 1998;21 Suppl 3:C7-C10.

37. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.

38. Fratiglioni L, von Strauss E, Qiu CK. Epidemiology of the dementias of old age. In Dening T, Jacoby R, Oppenheimer C, Thomas A, eds. The Oxford Textbook of Old Age Psychiatry. 4th ed. New York, NY: Oxford University Press; 2008: 391-406.

39. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403.

40. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287:329-336.

41. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol. 2004;61:1930-1934.

42. Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry. 2004;75:828-833.

43. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by African American relatives of patients with Alzheimer disease. Neurology. 2004;63:1560-1566.

44. Farrer LA, Sherbatich T, Keryanov SA, et al. Association between apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964-968.

45. Peters R, Poulter R, Warner J, Beckett N, Bulpitt C. Smoking, arterial hypertension, and risk of dementia: the Oxford Stroke Study. Lancet. 2005;6:1556-1560.

46. Rosengren A, Skoog I, Gustafsson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med. 2005;165:321-326.

47. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr., Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.

48. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009;66:336-342.

49. Stewart R, Masaki K, Xue QL, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2005;62:55-60.

50. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005;65:892-897.

51. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006;63:1312-1317.

52. Dahl AK, Löppönen M, Isoaho R, Berg S, Kivela SL. Overweight and obesity in old age are not associated with greater dementia risk. J Am Geriatr Soc. 2008;56:2261-2266.

53. Nourhashemi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P. Body mass index and incidence of dementia: the PAQUID study. Neurology. 2003;60:117-119.

54. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L. Late-life obesity mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc. 2008;56:111-116.

55. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.

56. Kivipelto M, Helkala EL, Laasko MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.

57. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet. 2005;4;487-499.

58. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.

59. Petitti DB, Crooks VC, Buckwalter JG, Chiu V. Blood pressure levels before dementia. Arch Neurol. 2005;62:112-116.

60. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58:1640-1646.

61. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60:223-228.

62. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61:1667-1672.

63. Ruitenbergen A, den Heijer T, Bakker SL, et al. Cerebral hyperperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005;57:789-794.

64. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005;26:157-163.

65. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Intern Med. 2006;63:686-692.

66. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of
of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165-1170.

84. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia. A prospective cohort study. Neurology. 2009;72:1727-1734.

85. Hofman LB, Schmieder J, Lessier GT, et al. Less Alzheimer disease pathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720-1726.

86. Kivipelto M, Heltkala EL, Laakso MP, et al. Apolipoprotein E A4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.

87. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277-281.

88. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Honolulu-Asia Aging Study. Arch Neurol. 2002;59:1689-1694.

89. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes associated with a reduced risk of dementia. Neurology. 2008;71:755-756.

90. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in prevalent dementia: results from the Framingham Study. Stroke. 2008;39:1136-1141.

91. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

92. Stadler R, White LR, Xue QL, Launer LJ. Twenty-six-year change in prevalent dementia: results from the Framingham Study. Stroke. 2008;39:1136-1141.

93. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

94. Kivipelto M, Heltkala EL, Laakso MP, et al. Apolipoprotein E A4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.

95. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to risk of dementia. Neurology. 2005;64:103-107.

96. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64:1689-1694.

97. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

98. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to risk of dementia. Neurology. 2005;64:103-107.

99. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

100. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia. A prospective cohort study. Neurology. 2009;72:1727-1734.

101. Hofman LB, Schmieder J, Lessier GT, et al. Less Alzheimer disease pathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720-1726.

102. Kivipelto M, Heltkala EL, Laakso MP, et al. Apolipoprotein E A4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.

103. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to risk of dementia. Neurology. 2005;64:103-107.

104. Solomon A, Käreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

105. Kivipelto M, Heltkala EL, Laakso MP, et al. Apolipoprotein E A4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.
Epidemiology of Alzheimer’s disease - Qiu et al

Dialogues in Clinical Neuroscience - Vol 11 • No 2 • 2009

disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet. 1999;354:919-920.

132. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343-353.

133. Qiu C, Bäckman L, Winblad B, Águedo-Torres H, Fratiglioni L. The influence of education on clinically diagnosed dementia: incidence and mortality data from the Kungsholmen Project. Arch Neurol. 2001;58:2034-2039.

134. Ngandu T, von Strauss E, Helkala EL, et al. Education and dementia: what lies behind the association? Neurology. 2007;69:1442-1450.

135. Karp A, Kärenholt I, Qiu C, Bellander T, Winblad B, Fratiglioni L. Relation of education and occupation-based socioeconomic status to incident Alzheimer’s disease. Am J Epidemiol. 2004;159:175-183.

136. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:569-574.

137. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet. 2000;355:1315-1319.

138. Wang HX, Karp A, Herlitz A, Crowe M, Kärenholt I, Winblad B, Fratiglioni L. Personality and lifestyle in relation to dementia incidence. Neurology. 2009;72:253-259.

139. Wang HX, Karp A, Winblad B, Fratiglioni L. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol. 2002;155:1081-1087.

140. Szczepniak JS, Pfeffer LA, Masaki K, et al. The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol. 2006;162:433-440.

141. Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer’s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5:406-412.

142. Lason EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;144:73-81.

143. Karp A, Paillard-Borg S, Wang HX, Silverstein M, Winblad B, Fratiglioni L. Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord. 2006;21:65-73.

144. Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. JAMA. 2004;292:1447-1453.

145. Rovio S, Kärenholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005;4:705-711.

146. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508-2516.

147. Crowe M, Andel R, Pedersen NL, Johansson B, Gatz M. Does participation in leisure activities lead to reduced risk of Alzheimer’s disease? A prospective study of Swedish twins. J Gerontol B Psychol Sci Soc Sci. 2003;58:P249-P255.

148. Wilson RS, Bennett DA, Bienias JL, Aggarwal NT, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology. 2002;59:1910-1914.

149. Wilson RS, Mendes De Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287:742-748.

150. Andel R, Crowe M, Pedersen NL, et al. Complexity of work and risk of Alzheimer’s disease: a population-based study of Swedish twins. J Gerontol B Psychol Sci Soc Sci. 2005;60:P251-P258.

151. Kröger E, Andel R, Lindsay J, Benonissia Z, Verreault R, Laurin D. Is complexity of work associated with risk of dementia? The Canadian Study of Health and Aging. Am J Epidemiol. 2008;167:820-30.

152. Valenzuela MJ, Sachdev P, Wen W, Chen X, Brodaty H. Lifespan mental activity predicts diminished rate of hippocampal atrophy. PLoS ONE. 2008;3:e2598.

153. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174.

154. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61:668-672.

155. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007;68:1902-1908.

156. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.

157. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 2008;70:17-24.

158. Arvanitakis Z, Grodstein F, Bienias JL, et al, Bennett DA. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70:2219-2225.

159. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:e33.

160. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800-1808.

161. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896-905.

162. Qiu C, Karp A, von Strauss E, Winblad B, Fratiglioni L, Bellander T. Lifetime principal occupation and risk of Alzheimer’s disease in the Kungsholmen project. Am J Ind Med. 2003;43:204-211.

163. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169:489-496.

164. Perl DP, Moalem S, Aluminum and Alzheimer’s disease, a personal perspective after 25 years. J Alzheimers Dis. 2006;9(suppl):291-300.

165. Fechting M, Jonsson F, Pedersen NL, Ahlborn A. Occupational magnetic field exposure and neurodegenerative disease. Epidemiology. 2003;14:413-419.

166. Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T. Occupational exposure to electromagnetic fields and risk of Alzheimer’s disease. Epidemiology. 2004;15:687-94.

167. Garcia AM, Sisternas A, Hoyos SP. Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis. Int J Epidemiol. 2008;37:329-340.

168. Sobel E, Dunn M, Davanipour Z, Qian Z, Chui HC. Elevated risk of Alzheimer’s disease among workers with likely electromagnetic field exposure. Neurology. 1996;47:1477-1481.

169. Fleming S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry. 2003;74:857-862.

170. Mehta KM, Ott A, Kalmijn S, et al. Head trauma and risk of dementia and Alzheimer’s disease: the Rotterdam Study. Neurology. 1999;53:1959-1962.

171. Himanen L, Portin R, Isometsä H, Helenius H, Kurki T, Tenovuo O. Longitudinal cognitive changes in traumatic brain injury: a 30-year follow-up study. Neurology. 2006;66:187-192.

172. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas C. Depressive symptoms, sex, and risk for Alzheimer disease. Ann Neurol. 2005;57:381-387.

173. Andersen K, Lolk A, Kragh-Sorensen P, Petersen NE, Green A. Depression and the risk of Alzheimer disease. Epidemiology. 2005;16:233-238.

174. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer’s disease: a 25-year prospective after 25 years. J Alzheimers Dis. 2006;9(suppl):291-300.

175. Qiu CX, De Ronchi D, Fratiglioni L. The epidemiology of the dementia: an update. Curr Opin Psychiatry. 2007;20:380-385.

176. McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease
for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4-5.

177. Peters R, Beckett N, Furet F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:689-699.

178. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291:2947-2958.

179. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004;291:2959-2968.

180. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.

181. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.

182. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253-2262.

183. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.

184. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.

185. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.

186. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.

187. Gibbs RB, Gabor R. Estrogen and cognition: applying preclinical findings to clinical perspectives. J Neurosci Res. 2003;74:637-643.

188. Jones RW, Kivipelto M, Feldman H, et al. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADE): design and baseline characteristics. Alzheimer’s Dement. 2008;4:145-153.

189. Cuckierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32:221-226.

190. Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementia. Lancet Neurol. 2006;5:87-96.

191. Richards M, Deary IJ. A life course approach to cognitive reserve: a model for cognitive aging and development? Ann Neurol. 2005;58:617-622.

192. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735-741.

193. Bäckman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer’s disease. Brain. 2001;124:96-102.

194. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830-834.

195. Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry. 2002;159:436-442.

196. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115-121.

197. Nordberg A. Amyloid imaging in Alzheimer’s disease. Curr Opin Neurol. 2007;20:398-402.

198. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1455-1465.

199. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.

200. Ridha BH, Barnes J, van de Pol LA, et al. Application of automated medial temporal lobe atrophy scale to Alzheimer disease. Arch Neurol. 2007;64:849-854.

201. Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry. 2006;77:429-438.

202. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69:1622-1634.

203. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008;3:CD002854.

204. Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians’ Health Study II. Arch Intern Med. 2007;167:2184-2190.

205. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774-1783.

206. Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease thera-